BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27713144)

  • 1. RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation.
    Yang J; Platt LT; Maity B; Ahlers KE; Luo Z; Lin Z; Chakravarti B; Ibeawuchi SR; Askeland RW; Bondaruk J; Czerniak BA; Fisher RA
    Oncotarget; 2016 Oct; 7(43):69159-69172. PubMed ID: 27713144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice.
    Dai YC; Wang SC; Haque MM; Lin WH; Lin LC; Chen CH; Liu YW
    PLoS One; 2017; 12(10):e0186214. PubMed ID: 29016672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis.
    Huang J; Stewart A; Maity B; Hagen J; Fagan RL; Yang J; Quelle DE; Brenner C; Fisher RA
    Oncogene; 2014 Jul; 33(27):3604-11. PubMed ID: 23995786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulator of G protein signaling 6 mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism.
    Huang J; Yang J; Maity B; Mayuzumi D; Fisher RA
    Cancer Res; 2011 Oct; 71(20):6310-9. PubMed ID: 21859827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulator of G protein signaling 6 is a novel suppressor of breast tumor initiation and progression.
    Maity B; Stewart A; O'Malley Y; Askeland RW; Sugg SL; Fisher RA
    Carcinogenesis; 2013 Aug; 34(8):1747-55. PubMed ID: 23598467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis.
    Iida K; Itoh K; Maher JM; Kumagai Y; Oyasu R; Mori Y; Shimazui T; Akaza H; Yamamoto M
    Carcinogenesis; 2007 Nov; 28(11):2398-403. PubMed ID: 17602169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.
    Hsu JW; Hsu I; Xu D; Miyamoto H; Liang L; Wu XR; Shyr CR; Chang C
    Am J Pathol; 2013 May; 182(5):1811-20. PubMed ID: 23499463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer.
    Ahlers KE; Chakravarti B; Fisher RA
    AAPS J; 2016 May; 18(3):560-72. PubMed ID: 27002730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder.
    Masuda N; Murakami K; Kita Y; Hamada A; Kamada M; Teramoto Y; Sakatani T; Matsumoto K; Sano T; Saito R; Okuno Y; Ogawa O; Kobayashi T
    Am J Pathol; 2020 Aug; 190(8):1752-1762. PubMed ID: 32339497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation.
    Lee CC; Yamamoto S; Wanibuchi H; Wada S; Sugimura K; Kishimoto T; Fukushima S
    Cancer Res; 1997 Nov; 57(21):4765-76. PubMed ID: 9354438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis.
    Iida K; Itoh K; Kumagai Y; Oyasu R; Hattori K; Kawai K; Shimazui T; Akaza H; Yamamoto M
    Cancer Res; 2004 Sep; 64(18):6424-31. PubMed ID: 15374950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele.
    Ozaki K; Sukata T; Yamamoto S; Uwagawa S; Seki T; Kawasaki H; Yoshitake A; Wanibuchi H; Koide A; Mori Y; Fukushima S
    Cancer Res; 1998 Sep; 58(17):3806-11. PubMed ID: 9731488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.
    Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL
    Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis.
    He Z; Kosinska W; Zhao ZL; Wu XR; Guttenplan JB
    Mutat Res; 2012 Feb; 742(1-2):92-5. PubMed ID: 22155125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of glutathione S-transferase M1 protein in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced mouse bladder carcinogenesis.
    Chuang JJ; Dai YC; Lin YL; Chen YY; Lin WH; Chan HL; Liu YW
    Toxicol Appl Pharmacol; 2014 Sep; 279(3):322-330. PubMed ID: 24998975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation.
    Li T; Huang M; Sun N; Hua X; Chen R; Xie Q; Huang S; Du M; Zhao Y; Lin Q; Xu J; Han X; Zhao Y; Tian Z; Zhang Y; Chen W; Shen X; Huang C
    J Exp Clin Cancer Res; 2024 Feb; 43(1):50. PubMed ID: 38365726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-Leucine and L-isoleucine enhance growth of BBN-induced urothelial tumors in the rat bladder by modulating expression of amino acid transporters and tumorigenesis-associated genes.
    Xie XL; Kakehashi A; Wei M; Yamano S; Takeshita M; Yunoki T; Wanibuchi H
    Food Chem Toxicol; 2013 Sep; 59():137-44. PubMed ID: 23747718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A functional polymorphism in RGS6 modulates the risk of bladder cancer.
    Berman DM; Wang Y; Liu Z; Dong Q; Burke LA; Liotta LA; Fisher R; Wu X
    Cancer Res; 2004 Sep; 64(18):6820-6. PubMed ID: 15375002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
    Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
    Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survivin gene signature predicts aggressive tumor behavior.
    Salz W; Eisenberg D; Plescia J; Garlick DS; Weiss RM; Wu XR; Sun TT; Altieri DC
    Cancer Res; 2005 May; 65(9):3531-4. PubMed ID: 15867343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.